Q1 2026 Revenue and Cash Position
26th May 2026
Focus
Our research and development programs target metabolic dysfunction-associated steatohepatitis (MASH).
Our pipeline
Science
The panNASH initiative contributes to a better understanding of MASH/NASH and the specific importance of panPPAR agonism in the treatment of this disease.
Pannash WebsitePartnerships
Licensing and collaboration agreements in place with Sino Biopharm and Hepalys Pharma, Inc.
Hepalys Pharma, Inc.Inventiva in Numbers
2
Partnerships (Sino Biopharm and Hepalys Pharma, Inc.)
2
Innovative Clinical Programs
80
People in our Scientific Team
12
Patent Families
A Library of
240,000
Compounds
Welcome to Inventiva Pharma
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
Our activities are currently focused on the development of lanifibranor, a next-generation drug candidate being evaluated in the pivotal Phase 3 NATiV3 trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis.
About InventivaFinancial Information
Latest Results
Upcoming Events
First-Half 2026 Revenue and Cash Position
29th July 2026
Euronext Share Information
€4.385 -3.73%Last update: Apr 09, 2026 at 17:35 CET
Open: €4.57
Previous close: €4.555
Day High: €4.58
Day Low: €4.365
Therapeutic Areas
MASH/NASH
Inventiva is developing lanifibranor for the treatment of MASH to address all the key features of this disease: accumulation of liver fat (steatosis), inflammation (hepatitis), injury of liver cells (ballooning), as well as scarring of the liver (fibrosis) that can ultimately lead to cirrhosis. The progression of fibrosis to cirrhosis, and its complications, is especially relevant in determining the outcome of the disease with regard to morbidity and survival.
Lanifibranor has completed a phase IIb study. After 6 months of treatment, lanifibranor showed statistically significant efficacy for the regulatory endpoints required by FDA and EMA: resolution of MASH* without worsening of fibrosis, reduction in fibrosis without worsening of MASH** and in the composite endpoint of patients achieving resolution of MASH with improvement in fibrosis. These efficacy results, together with a favorable safety profile, led to Breakthrough Therapy Designation by the FDA. For more details of the headline results see the results presentation.
Based on the positive results of the phase IIb study, Inventiva has initiated a pivotal phase III clinical trial, NATiV3, evaluating lanifibranor for the treatment of MASH.
[Clinicaltrials.gov NCT04849728].
* Resolution of MASH and no worsening of fibrosis at week 24: NAS-I = 0 or 1 (NAS-Inflammation), NAS-B = 0 (NAS-Ballooning) and no worsening of NAS-F from baseline (NAS-Fibrosis)
** Improvement of liver fibrosis ≥ 1 stage and no worsening of MASH at week 24
